The clinical impact of these findings was confirmed by an increased expression of HRH2 and CREB5 in HCC patients, and a significant association of HRH2/CREB5 expression with patient overall survival and enhanced HCC risk in several clinical cohorts (Fig. 7). This evidence concerns the gene CREB5 and hepatocellular carcinoma.